Golden
Cambridge Bio-Augmentation Systems

Cambridge Bio-Augmentation Systems

Cambridge Bio-Augmentation Systems is a company designing and developing hardware and software interface between the human nervous system and external devices to treat chronic diseases.

Cambridge Bio-Augmentation Systems, or BIOS (as of December, 2018), is a company that is aiming to create neural interfaces between AI and the nervous system. 



Founded by Emil Hewage and Oliver Armitage, the company has the goal to build a link between the body's nervous and external devices for the sake of aiding against chronic diseases. The link is not designed to communicated directly with the such things as the spine or brain, but rather to decipher the signals that are sent to and from problematic/diseased organs or limbs, and then using a new signal to help treat the patient. The company's main targets are heart disease and diabetes.Another use for this neural link that BIOS offers is for a prosthetic interface device, or PID. With BIOS, a patient with a missing limb would be able to control an artificial body part.



BIOS uses machine learning to process high volumes of neural data in order to understand how each signal corresponds to which action in a patient. They are also making this data available to anybody involved in healthcare.

Timeline

December 4, 2018

BIOS raises $4.5M to further develop neural interface

People

Name
Role
LinkedIn

Emil Hewage

Founder



Oliver Armitage

Founder



Philipp Moehring

Investor



Further reading

Title
Author
Link
Type
Date









Documentaries, videos and podcasts

Title
Date
Link





Companies

Company
CEO
Location
Products/Services









References